Additionally, FA was validated to reduce microglial aggregation, with our results indicating a significant decrease in GFAP and Iba-1 levels, suggesting polyphenolic compounds might mitigate the activation of astrocytes and microglia [29,30], but its role in AD has not been uncovered yet. The gene discussed is GFAP; the disease is Alzheimer disease.